Document:

2007 Compensation Information for Executive Officers

 Exhibit 10.10 
 2007 COMPENSATION INFORMATION FOR EXECUTIVE OFFICERS 
 The table below provides certain information
regarding (i) the annual base salaries as of January 1, 2007 (except as noted) of the current and former executive officers of Kosan Biosciences Incorporated (the “Company”) listed below; (ii) the cash bonuses awarded to the
current and former executive officers of the Company listed below under the Company’s 2007 Executive Officer Cash Bonus Plan (the “Bonus Plan”); and (iii) the number of shares of the Company’s common stock subject to stock
options granted in January 2007 (except as noted) to the current and former executive officers of the Company listed below: 
  

							
	 Executive Officer
	  	2007 Annual
Base Salary
($)	  	Cash Bonus
Award
($)	  	Number of
Shares Subject
to Stock
Options (#)5
				
	 Gary S. Titus, C.P.A.
	  	312,000	  	99,782	  	15,000
	 Senior Vice President and Chief Financial Officer
	  		  		  	
				
	 Pieter J. Licari
	  	254,000	  	73,438	  	37,500
	 Senior Vice President, Manufacturing and Operations
	  		  		  	
				
	 Pieter B.M.W.M. Timmermans
	  	260,000	  	71,273	  	37,500
	 Senior Vice President, Drug Discovery and Preclinical Development
	  		  		  	
				
	 Jonathan Wright1
	  	280,000	  	—  	  	140,000
	 Senior Vice President, General Counsel and Secretary
	  		  		  	
	 Robert G. Johnson, Jr.2
	  	416,000	  	165,672	  	100,000
	 Former President and Chief Executive Officer
	  		  		  	
				
	 Margaret A. Horn3
	  	312,000	  	—  	  	45,000
	 Former Senior Vice President, Legal and Corporate Development, General Counsel and Secretary
	  		  		  	
				
	 Robert De Jager4
	  	326,000	  	—  	  	—  
	 Former Senior Vice President, Clinical Development and Chief Medical Officer
	  		  		  	

  

	 1
	 Mr. Wright was appointed as the Company’s Senior Vice President, General Counsel and Secretary effective
December 4, 2007. Mr. Wright was not a participant in the Company’s 2007 Executive Officer Cash Bonus Plan. The option granted to Mr. Wright as shown in the table above was granted in November 2007. 

 

	 2
	 Dr. Johnson resigned as the Company’s President and Chief Executive Officer effective February 27, 2008.

  

	 3
	 Ms. Horn resigned as the Company’s Senior Vice President, Legal and Corporate Development, General Counsel and
Secretary effective August 24, 2007. 

  

	 4
	 Dr. De Jager resigned as the Company’s Senior Vice President, Clinical Development and Chief Medical Officer
effective August 8, 2007. 

  

	 5
	 Stock options vest over a period of four years subject to continuous service and were granted with an exercise price
equal to the fair market value on the date of grant (as determined in accordance with the Company’s 2006 Equity Incentive Plan).2008 Compensation Information for Executive Officers

 Exhibit 10.43 
 2008 COMPENSATION INFORMATION FOR EXECUTIVE OFFICERS 
 The table below provides certain information
regarding (i) the annual base salaries as of January 1, 2008 (except as noted) of the current and former executive officers of Kosan Biosciences Incorporated (the “Company”) listed below; (ii) the target cash bonus awards
established for the current and former executive officers of the Company listed below under the Company’s 2008 Executive Officer Cash Bonus Plan (the “Bonus Plan”), expressed as a percentage of applicable base salary; (iii) the
number of shares of the Company’s common stock subject to stock options granted in January 2008 to the executive officer of the Company listed below; and (iv) the number of restricted stock units (“RSUs”) granted in January 2008
to the current and former executive officers of the Company listed below: 
  

									
	 Executive Officer
	  	2008 Annual
Base Salary
($)	  	2008 Target
Bonus
(%)	  	Number of
Shares Subject
to Stock
Options (#)3	  	Number
of RSUs
(#)4
	 Helen Kim1
	  	280,000	  	35	  	140,000	  	15,100
	 President and Chief Business Officer
	  		  		  		  	
					
	 Gary S. Titus, C.P.A.
	  	322,000	  	35	  	—  	  	32,200
	 Senior Vice President and Chief Financial Officer
	  		  		  		  	
					
	 Pieter J. Licari
	  	270,000	  	35	  	—  	  	32,200
	 Senior Vice President, Manufacturing and Operations
	  		  		  		  	
					
	 Pieter B.M.W.M. Timmermans
	  	270,000	  	35	  	—  	  	32,200
	 Senior Vice President, Drug Discovery and Preclinical Development
	  		  		  		  	
					
	 Jonathan Wright
	  	280,000	  	35	  	—  	  	15,100
	 Senior Vice President, General Counsel and Secretary
	  		  		  		  	
	 Robert G. Johnson, Jr.2
	  	430,000	  	45	  	—  	  	68,103
	 Former President and Chief Executive Officer
	  		  		  		  	

  

	 1
	 Ms. Kim was appointed as the Company’s Senior Vice President and Chief Business Officer on January 3,
2008 and was appointed as the Company’s President effective February 27, 2008. 

  

	 2
	 Dr. Johnson resigned as the Company’s President and Chief Executive Officer effective February 27, 2008.

  

	 3
	 Option vests over a period of four years subject to continuous service and was granted with an exercise price equal to
the fair market value on the date of grant (as determined in accordance with the Company’s 2006 Equity Incentive Plan). 

  

	 4
	 The RSUs vest as follows: (i) 50% of RSUs will vest, if at all, if the executive officer remains an employee of the
Company through December 31, 2008 and the Company has entered into a written agreement on or before a specified date with a pharmaceutical or biotechnology company for the development and commercialization of a Company-developed Hsp90 inhibitor
and/or epothilone product, provided such agreement includes certain minimum financial terms, (ii) another 25% of the RSUs will vest, if at all, if the executive officer remains an employee of the Company through December 31, 2009 and
(iii) another 25% of the RSUs will vest, if at all, if the executive officer remains an employee of the Company through December 31, 2010. In the event that one or more RSUs vest, the Company will deliver to the executive officer one share
of the Company’s common stock for each RSU that has vested.Employment Agreement - Helen S. Kim

 Exhibit 10.45 
 

 
 December 5, 2007 
 Helen S.
Kim 
 [Address] 
  
 Dear Helen: 
 On behalf of Kosan Biosciences Incorporated (“Kosan” or the “Company”), I am pleased to
extend to you an offer of employment for the position of Sr. Vice President and Chief Business Officer reporting to me. This letter sets forth the terms and conditions of your employment with Kosan. Please read it carefully.  
 Your initial monthly base salary will be $23,333.33 ($280,000 on an annualized basis). Also, you will be eligible to participate in our annual performance bonus program
and can earn a performance bonus of up to 35% of your annual base salary, based on achieving your personal performance goals and objectives, and Kosan’s achievement of its Corporate goals and objectives. The applicable goals and objectives will
be determined by the Company in its sole discretion and provided to you in writing. The Company will determine whether the applicable goals and objectives have been achieved, and the amount of any earned bonus. In addition, you must remain employed
through the end of the year in order to earn an annual bonus. 
 As a full-time regular employee, you will be eligible to participate in the Company’s
general employee benefits, including but not limited to health care coverage, life and disability insurance coverage, and automatic enrollment in our 401(k) plan, pursuant to the terms and conditions of the applicable benefit plans. Your personal
coverage under Kosan’s current benefit plans will become effective on your first day of full-time work at Kosan (your “start date”). The Company retains the discretion to modify your compensation (including base salary and annual
bonus program) and benefits from time to time, in its sole discretion. 
 You will work out of the Company’s corporate offices in Hayward, California.
Normal business hours are from 8:30 a.m. to 5:30 p.m., Monday through Friday. As an exempt salaried employee, you will be expected to work additional hours as required by the nature of your work assignments, and you will not be eligible for overtime
pay. Your start date will be as soon as can be arranged, but no later than January 3, 2008. 
 As soon as your employment commences, we will recommend
to Kosan’s Board of Directors (the “Board”) or appropriately authorized members of senior management (“Senior Management”) that you be granted an option to purchase 140,000 shares of Kosan Common Stock under the Kosan Stock
Option Plan (the “Plan”) at an exercise price equal to the fair market value of the stock on the date of grant as determined by the Board or Senior Management, as applicable. The option shares will vest over four years conditioned upon
your 

  

 3832 Bay Center Place, Hayward, CA 94545. Tel: (510)732 8400. Fax: (510)732 8401 
 Web Site: http://www.kosan.com 

 
continued service to the Company (as defined in the Plan), with one-fourth vesting after one year of continued service and the remainder vesting in equal
monthly increments over the remaining three years as provided in the Plan and your stock option agreement. The option grant will be governed in full by the Plan and your grant documentation, including your stock option agreement. 
 This offer of employment is contingent upon your successfully passing a background check pursuant to your written authorization, as well as the Company’s receipt of
positive references. Your employment with the Company is for no specified period and constitutes at will employment. As a result, you are free to resign at any time, for any reason or for no reason. Similarly, the Company is free to conclude its
employment relationship with you at any time, with or without cause, and with or without advance notice. In addition, the Company may change other terms and conditions of your employment at its discretion at any time, including but not limited to
your job position, duties, reporting relationship, work schedule, and office location. 
 As a condition of your employment, you must carefully review, sign,
and comply with the enclosed Employee Proprietary Information and Invention Assignment Agreement. Also as a condition of your employment, you agree to abide by the Company’s policies and procedures, as adopted from time to time, and agree to
refrain from any activities that conflict with your obligations to the Company. You represent that you do not have any agreements with any third parties (e.g., former employers), including but not limited to non-competition or proprietary
information agreements, that will conflict with or limit your ability to discharge your duties to Kosan unless such agreements were previously disclosed to Kosan. You agree that, in the course of your work for Kosan, you will not make unauthorized
use or disclosure of any confidential information or materials, including trade secrets, of any former employer or other third party. Rather, you will be expected to use only that information generally known and used by persons with training and
experience comparable to your own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise lawfully provided or developed by the Company or by you on behalf of the Company. You represent that you
will be able to perform your employment duties within the guidelines described in this paragraph. 
 The Immigration Reform and Control Act of 1986 requires
that every person present to potential employers proof of identity and eligibility or authorization to accept employment in the United States. In order to comply with this law, this offer is contingent upon your ability to provide appropriate
documentation to prove both your identity and legal eligibility to be employed by Kosan. Acceptable forms of documentation are described on the attachment to this offer letter. Please be sure to bring this documentation with you on your first day of
employment.  
 This letter (together with your Employee Proprietary Information and Inventions Agreement and any stock option grant agreement you
receive) constitutes the complete and exclusive statement of your agreement with Kosan concerning the subject matter hereof. The terms of this letter agreement supersede any other agreements or promises made to you by anyone, whether oral or
written. The terms of this letter agreement cannot be changed (except with respect to those changes expressly reserved to Kosan’s discretion in this letter) without a written agreement signed by you and a duly authorized officer of Kosan.

 We are very excited at the prospect of your joining Kosan Biosciences and becoming a key contributor to our efforts.
Please do not hesitate to contact Human Resources if you have any questions. This offer will remain open until December 6, 2007 at which time it will expire if you have not returned the fully signed letter to us. 
 To indicate your acceptance of our offer, please sign and date one copy of this letter and the Employee Proprietary Information and Invention Assignment Agreement and
return them to me. 
 Sincerely, 
  

									
	Kosan Biosciences	 		 	UNDERSTOOD AND ACCEPTED
				
	By:	 	/s/ Robert G. Johnson, Jr.	 		 	/s/ Helen S. Kim
	Robert G. Johnson, Jr., MD, PhD	 		 	Helen S. Kim
	President & Chief Executive Officer	 		 	
		 		 	Date: December 6, 2007
		 		 	Date your employment begins:
			
		 		 	January 3, 2008

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}]]